Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Broadcom

Carnival

Delta Air Lines

Generac Holdings

Norwegian Cruise Line

NVIDIA

PulteGroup

Royal Caribbean Cruises

In the second quarter of 2023, certain companies within the S&P 500 exhibited remarkable returns, indicating their robust performance and investor interest.

10 S&P 500 stocks with the best returns in 2Q, 2023

Eli Lilly is working on a molecule that might be better than Novo Nordisk's Ozempic. It already has another medicine on the market that could be better.

Eli Lilly Could Be Making The Next Ozempic, but Should You Buy the Stock?

Eli Lilly and Company continues to make impressive progress when it comes to its obesity and diabetes medications. Shares have already shot up in recent months because of this, but this is likely the beginning of strong financial results for the firm. While risks to exist, the overall picture for the company does look bullish at this point in time.

Eli Lilly: Miracle Drug Progress Offers Shareholders More Upside

AbbVie

Merck

Pharmaceutical stocks have not shared in this year's bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%.

The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023

Eli Lilly stock (NYSE: LLY) currently trades at $459 per share, roughly 150% above its level in March 2021.

Will Eli Lilly Stock Continue To Rise After 40% Gains In The Ongoing Inflation Shock?

Oracle

Knowing when to sell a stock can be as important as knowing when to buy it. This can be especially difficult with dividend stocks.

3 Dividend Stocks That Have Insiders Running for the Exit

Sigilon Therapeutics

Shares of Sigilon Therapeutics Inc (NASDAQ: SGTX) soared more than 500% today after Eli Lilly & Co (NYSE: LLY) said it will buy the biopharmaceutical company in a deal worth up to $309.6 million. Details of the Lilly-Sigilon agreement Lilly has agreed to pay a total of up to $126.

Eli Lilly to buy Sigilon Therapeutics on a massive premium

Eli Lilly said it will acquire Sigilon Therapeutics in an all-cash deal worth up to $309.6 million.

Eli Lilly to Acquire Sigilon Therapeutics

Eli Lilly and Co (NYSE:LLY) shares are up again Thursday as its weight loss drug retatrutide continues to garner attention from investors and analysts alike.  UBS reiterated its Buy rating and $498 price target for the company following the results of a Phase 2 trial which found that patients treated with injectible retatrutide saw a median weight loss of 58 pounds, or 24.2%, after 48 weeks.

Eli Lilly's weight loss drug 'sets a new bar' with remarkable Phase 2 results

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 500%

Novo Nordisk

Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors said in a report Thursday. A decades-old law generally prohibits Medicare from covering prescription drugs for weight loss.

Medicare coverage of weight-loss drugs? Don't count on it, analysts say.

Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.

Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments

Eli Lilly & Co. LLY, -1.25% said Thursday it has agreed to acquire Sigilon Therapeutics in a deal worth up to $309.6 million, sending Sigilon's stock up more than 470% premarket. Under the terms of the deal, Lilly will pay $14.92 per Sigilon share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest.

Sigilon Therapeutics' stock soars 472% after Eli Lilly agrees to acquire company

INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

Lilly to Acquire Sigilon Therapeutics

GlaxoSmithKline

Artificial intelligence is being used by the world's top drugmakers to speed up innovation in areas of high unmet medical need. GSK and Eli Lilly are both pioneers in the use of AI for drug discovery and development.

Better Artificial Intelligence Stock: GSK or Eli Lilly?

Eli Lilly's orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and ease of use.

As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge

Pfizer

Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.

Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know.

Eli Lilly shares rose in early trading on Tuesday after a trial showed its retatrutide weight loss drug could help patients lose more weight than other drugs, including Novo Nordisk's Ozempic.

Eli Lilly Shares Rise After Drug Helps Patients Lose More Weight Than Competitors

Eli Lilly may have a best-in-class obesity care asset. In a mid-stage study, the drugmaker's weight loss drug produced a mean weight reduction of 24.2% at 48 weeks.

Why Eli Lilly Stock Briefly Popped Today

Eli Lilly And Co (NYSE:LLY) released mid-stage trial data earlier today showing its obesity drug candidate promoted weight loss of up to 24.2% after 48 weeks, beating competitors' results.

Eli Lilly Stock Nabs Record on Obesity Drug Trial Data

Altimmune

Amgen

Viking Therapeutics

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

Factbox: Weight-loss drugs: the next gold rush

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Eli Lilly Sets New Bar In Weight Loss And Nears Record High; Novo Nordisk Slips

Shares of Eli Lilly & Co. LLY, -1.33% gained 1.6% premarket on Tuesday after the company released new data late Monday on its investigational obesity drug retatrutide. The treatment resulted in average weight loss of up to 17.5%, or 41.2 pounds, after 24 weeks in patients with obesity or overweight and without diabetes, and average weight loss of up to 24.2%, or 57.8 pounds, after 48 weeks, according to results presented at the American Diabetes Association's scientific conference.

Eli Lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average

UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS).

More evidence needed on Lilly's weight loss drug, UK watchdog says

A new drug to tackle obesity cut the weight of participants by an average of 58 pounds at the end of its latest clinical trial, US drug giant Eli Lilly announced last night. Results from the trial of the new injectable drug retatrutide were released in the New England Journal of Medicine (NEJM) and The Lancet on Monday with clinicians said to be stunned by the weight loss achieved.

News for Eli Lilly Stock (LLY)